Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: Clinical efficacy and potential mechanisms of action

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 285-296

  Lytton, Simon D ^a   Denton, Christopher P ^b   Nutzenberger, Achim M ^c  

^a SeraDiaLogistics   (Germany)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c Ophthalmology Consultant   (Germany)

Author keywords

Meta analysis; Mode of action; Polyclonal anti T lymphocyte globulin; rATG; Regulatory T cell; T cell depletion

Indexed keywords

ETANERCEPT; GLOBULIN; INTERLEUKIN 10; INTERLEUKIN 7 RECEPTOR; METHOTREXATE; METHYLPREDNISOLONE; RABBIT ANTI T LYMPHOCYTE GLOBULIN; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CD25+ T LYMPHOCYTE; CELL MEMBRANE; CONFERENCE PAPER; CONFIDENCE INTERVAL; DIFFUSE SCLERODERMA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCLUSION BODY MYOSITIS; INFLAMMATION; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MITOGENESIS; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; REGULATORY T LYMPHOCYTE; RESPIRATORY DISTRESS SYNDROME; RESPONSE VARIABLE; RISK; SERUM SICKNESS; T CELL DEPLETION; VASCULITIS;

ORYCTOLAGUS CUNICULUS;

EID: 35748953121     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.030     Document Type: Conference Paper

References (39)

1. SHENTON, B.K., M.D. WHITE, A.E. CLARK, et al. 1994. The paradox of ATG monitoring in renal transplantation. Transpl. Proc. 26: 3177-3180.
2. MUELLER, T.F., S.O. GREBE, B. RECKZEH, et al. 1999. Short-and long-term effects of polyclonal antibodies. Transpl. Proc. 31: 12S-15S.
3. VAN DE LINDE, P., O.M. TYSMA, J.P. MEDEMA, et al. 2006. P. Mechanisms of antibody immunotherapy on clonal islet reactive T cells. Hum. Immunol. 67: 264-273.
4. MICHALLET, M.P., F. SALTEL, M. FLACHER, et al. 2003. Caspase-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion. Blood 102: 3719-3726.
5. ROWINSKI, W., G. KORCYAK-KOALSKA, R. SAMSEL, et al. 2002. Can the immunosuppressive effect of perioperative single high-dose antithymocyte globulin administration in kidney allograft recipients be due to apoptosis of activated lymphocytes? Transpl. Proc. 34: 1622-1624.
6. GUTTMANN, R.D., P. CAUDRELIER, G. ALBERICI, et al. 1997. Pharmacokinetics, foreign protein immune response, cytokine release and lymphocyte subsets in patients receiving thymoglobulin and immunosuppression. Transpl. Proc. 29: 24S-26S.
7. KADEN, J. 2002. Eleven years intraoperative ATG bolus. A list of successes. Ann. Transpl. 7: 4-10.
8. SIMON, T., G. OPELZ, R. WEIMER, et al. 2003. The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant. Clin. Transpl. 17: 217-224.
9. STEEN, V.D. & T.A. MEDSGER. 1998. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 41: 1613-1619.
10. KENNEDY, G.A., J. BUTLER, R. WESTERN, et al. 2006. Combination antithymocyte globulin and soluble TNFa inhibitor (etanercept)+/?mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. BMT 37: 1143-1147.
11. BOCK, H.A. 1995. A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation 59: 830-840.
12. WEIMER, R., A. STAAK, C. SÜSAL, et al. 2005. ATG induction therapy:long-term effects on Th1 but not Th2 responses. Transpl. Int. 18: 226-236.
13. EIERMANN, T.H., P. LAMBRECHT & A.R. ZANDER. 1999. Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. BMT 23: 779-781.
14. LOPEZ, M., M.R. CLARKSON, M. ALBIN, et al. 2006. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J. Am. Soc. Nephrol. 17: 2844-2853.
15. PISTILLO, M.P., P.L. TAZZARI, F. BONIFAZI, et al. 2002. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukaemic patients. Transplantation 73: 1295-1302.
16. BEIRAS-FERNANDEZ, A., D. CHAPPEL, C. HAMMER, et al. 2006. Influence of polyclonal anti-thymocyte globulins upon ischemia-reperfusion injury in a nonhuman primate model. Transpl. Immunol. 15: 273-279.
17. SAUDEK, F., T. HAVRDOVA, P. BOUCEK, et al. 2004. Polyclonal anti-T cell therapy for type I diabetes mellitus of recent onset. Rev. Diab. Stud. 1: 80-88.
18. PEARL, J.P., J. PARRIS, D.A. HALE, et al. 2005. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am. J. Transpl. 5: 465-474.
19. OPELZ, G., C. NAUJOKAT, V. DANIEL, et al. 2006. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 81: 1227-1233.
20. AYUK, F. et al. 2005. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp. Hematol. 33: 1531-1536.
21. RADBRUCH, A. et al. 2006. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6: 741-750.
22. SHOENFELD, Y. & KATZ, U. 2005. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 38: 123-113.
23. SMITH, K.G. et al. 2006. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 54: 2970-2982.
24. SALVI, M. et al. 2007. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol. 156: 33-40.
25. FANG, L., B. FEHSE, M. ENGEL, et al. 2005. Anti-thymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 79: 369-371.
26. GILLET-HLADKY, S. et al. 2006. Rabbit antithymocyte globulin inhibits monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2,3-dioxygenase. Transplantation 82: 965-974.
27. NAUJOKAT, C., C. BERGES, D. FUCHS, et al. 2007. Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation 83: 485-497.
28. LIU, W., A.L. PUTNAM, Z. XU-YU, et al. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J. Exp. Med. 203: 1701-1711.
29. ARBOGAST, H. 2006. Efficacy and safety of a combined polyclonal-monoclonal induction regime in renal transplantation.World Transplantation Congress (Abstract #669).
30. ALEXANDER, T., A. RADBRUCK & F. HIEPE. 2006. Thymic rebound after autologous stem cell transplantation in SLE Annual European Congress of Rheumatology (EULAR Abstract OP0096).
31. TARKOWSKI, A., B. ANDERSSON-GÄRE & M. AURELL. 1993. Use of anti-thymocyte globulin in the management of refractory systemic autoimmune disease. Rheumatology 22: 261-266.
32. TARKOWSKI, A. & LINGREN, C. 1994. Beneficial effects of antithymocyte globulin in severe cases of progressive systemic sclerosis. Transpl. Proc. 26: 3197-3199.
33. STRATTON, R.J., H. WILSON & C.M. BLACK. 2001. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 40: 84-88.
34. SCHMITT, W.E.C., C. HAGEN, I. NEUMANN, et al. 2004. Treatment of refractory Wegener's granulomatosis with anti-thymocyte globulin (ATG): An open study in 15 patients European Vasculitis Study Group. Kidney Int. 65: 1440-1448.
35. HOUGH, R.E., J.A. SNOWDEN & N.M. WULFFRAAT. 2005. Haemopoietic stem cell transplantation in autoimmune diseases: a European perspective. Brit. J. Haematol. 128: 1365-2141.
36. NIHTYANOVA, S.I., G.M. BROUGH, C.M. BLACK, et al. 2006. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology 46: 442-445.
37. LINDBERG, C., E. TRYSBERG, A. TARKOWSKI, et al. 2003. Anti-T-lymphocyte globulin treatment in inclusion body myositis. Neurology 61: 260-262.
38. KEYMEULEN, B., E. VANDEMEULEBROUCKE, A.G. ZIEGLER, et al. 2005. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352: 2598-2608.
39. HEROLD, K.C., S.E. GITELMAN, U. MASHARANI, et al. 2005. A single course of anti-CD3 monoclonal antibody hOKT3 1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54: 1763-1769.